

**Minutes of the**

**4<sup>th</sup> Annual General Meeting**

of the shareholders of

**medmix Ltd**

held on

**Wednesday, 23 April 2025, 10.00 a.m.**

at

Lorzensaal, Dorfplatz 3, 6330 Cham, Switzerland

The chairman of the Board of Directors of medmix Ltd (the "**Chairman**"), Rob ten Hoedt, formally opens the 4<sup>th</sup> Annual General Meeting of medmix Ltd at 10.00 a.m. He welcomes the shareholders in German and explains that the meeting will be held in English to reach medmix' stakeholders worldwide. He then continues in English, introduces himself and notes the following:

The invitation to today's Annual General Meeting was published in the Swiss Official Gazette of Commerce on 27 March 2025. This means that the statutory notice period of 20 days has been complied with. The agenda and the proposals were also sent to the shareholders on 27 March 2025.

Pursuant to Art. 699a and Art. 734 of the Swiss Code of Obligations ("**CO**"), the annual report, the compensation report and the auditor's reports must be made available to the shareholders no later than 20 days before the Annual General Meeting. This is the case. The complete annual report, including the compensation report, the sustainability report and the auditor's reports, has been available on medmix' website since 26 February 2025. Furthermore, the résumés of the members of the Board of Directors proposed for re-election are available on medmix' website.

In advance of the Annual General Meeting, no requests for the inclusion of items on the agenda were received from shareholders, nor were there any counterproposals or questions regarding items on the agenda.

The meeting is therefore convened in accordance with the law and the articles of association of medmix Ltd and constitutes a quorum with regard to the published agenda items.

The Chairman welcomes and introduces the members of the Board of Directors attending the meeting. He then welcomes and introduces the members of the Executive Committee. He explains that René Willi stepped down as member of the Board of Directors and took up his role as Chief Executive Officer on 1 June 2024. The Chairman notes that René Willi has spent the last 25 years in healthcare and brings extensive experience from the pharma, diagnostics and medical device industry to lead medmix into the next stage of profitable growth. Having been a member of the Board of Directors since 2022, René Willi has a deep knowledge and understanding of medmix and its strategic development opportunities. The Chairman continues by introducing Jasper Den Ouden who joined medmix as Chief Human Resources and Sustainability Officer in March 2025. He states that Jasper Den Ouden brings extensive international HR leadership experience, having served as Chief Human Resources Officer at SR Technics Group most recently. The Chairman leads shareholders through Jasper Den Ouden's career and education and welcomes him to medmix.

The Chairman then welcomes Simon Niklaus, representing KPMG AG, Zurich, as well as Gian Andri Töndury, representing the independent proxy, Proxy Voting Services GmbH.

The Chairman hands over to Gian Andri Töndury who confirms that he has provided the Board of Directors with general information on the voting instructions received from shareholders no earlier than three working days prior to the Annual General Meeting. This general information included a summary of the yes-votes, no-votes, and abstentions for all agenda items.

The Chairman states that, in accordance with Art. 14 of the articles of association, today's Annual General Meeting is chaired by Rob ten Hoedt as Chairman. Xavier Schops acts as secretary. The Chairman then welcomes the vote counters, Mato Banovic (Zürcher Kantonalbank) and Daniel Schmidt-Badoux (Commerzbank AG, Zurich branch office).

The Chairman states that the minutes of last year's Annual General Meeting have been made available on medmix' website within the statutory period.

The Chairman explains the functioning of the electronic voting devices that the shareholders received. For the vote on the discharge under agenda item 3, the voting devices of those shareholders who are not legally allowed to take part in this vote have been blocked in the system. Tiwel Holding AG also voluntarily accepted this restriction. The Chairman asks the shareholders to participate in a test question to check the functioning of their device.

The Chairman then explains that the Annual General Meeting shall pass resolutions on each of today's agenda items by a majority of the votes represented, in accordance with art. 15 para. 1 of the articles of association.

The Chairman explains where shareholders can register should they wish to speak and points out that the meeting will be recorded on video.

The Chairman hands over to the Chief Executive Officer.

### **Speech by René Willi, Chief Executive Officer**

René Willi welcomes the shareholders in German and continues in English, stating the following:

"I am very pleased to present the key figures of our full year 2024 results to you today. At last year's AGM – in my speech as designated CEO of medmix – I said that we had to start navigating through stormy seas, but we also know that stormy seas create the best sailors. Looking back to 2024, this analogy still applies: the seas continued to be rough, but we were able to navigate the stormy seas well and set sail to pick up speed in our journey towards continued profitable growth.

We managed to increase gross profit and maintain profitability at the upper range of our revised guidance, despite slightly decreased revenues. We are very pleased with our cash generation, as we managed to substantially increase both operating net cash flow and free cash flow.

Another highlight of 2024 was our improved sustainability ranking by CDP, a globally recognized organization that evaluates companies' environmental impacts and initiatives. We moved from "taking coordinated actions on climate issues" (which is a B) to "implementing current best practices" (which is an A).

Furthermore, we have launched a growth and efficiency program which is aimed at 2 main goals: First, unleashing growth by re-allocating resources to our strategic priorities, and second, improving our performance by strategically reducing costs. Through this program, we target cost out of 30 million Swiss francs, with most of the actions to be executed in 2025, and a significant portion of the savings expected to have an impact already in 2025.

On this slide [referencing the slide "Highlights Full Year 2024"], you see our highlights for 2024. As mentioned, we are very pleased with our cash generation – net working capital management and lower CAPEX were the key drivers for this very positive result. Adjusted EBITDA margin was stable year on year on a more favorable mix due to higher dental sales and an increase of operating expenses due to our new facilities in Atlanta and Qiaoyi.

In Q4, we have concluded our strategy review in order to create a sound foundation for future sustainable growth. We have analyzed our organizational setup and our businesses along five pillars: 1) customer centricity, 2) innovation, 3) operational excellence and cost discipline, 4) portfolio as well as 5) our culture.

Let me now talk about the outlook, which I'm sure is of great interest to you. 2025 will be a transition year. We expect our healthcare segment revenues to be flat year on year, with dental and surgery business units growing strongly, offset by a decline in our drug delivery business unit due to dual sourcing. Material device revenue from our two new platforms is only starting towards the end of 2026. We expect our consumer & industry segment to be flat due to continued uncertainty in our various end markets. Newly announced tariffs increased uncertainty as well. We continue to leverage our U.S. facilities and executing our local for local strategies. As an example, we progressed in in-sourcing strategies for surgery and industry as well as investing in our drug delivery manufacturing in Atlanta. We have also invested in our beauty manufacturing in Elgin, close to Chicago, and launched globally with our largest beauty customer a new product with production in the U.S. for the U.S. We have some exposure in our dental business unit and are working closely with our customers to mitigate the impact. Our global manufacturing network offers clear advantages and we are in a good position to seize the opportunities that arise.

On this basis, we expect revenues in 2025 to be flat on an FX adjusted basis. We will lay the important foundations for a stronger and more resilient future in 2025. We will see the first impacts of our growth and efficiency program, but these will be partly offset by the cost of some of the programs we launch and re-investment in our growth

opportunities. For this reason, we anticipate that our adjusted EBITDA margin in 2025 will be between 18% and 19%.

Looking further forward: In the midterm - over a three-year period - we expect a compound annual growth rate in revenues of above 4% and an adjusted EBITDA margin above 20%.

We believe that the strategic priorities we have identified and the steps we have taken in 2024 will enable us to succeed even if the underlying markets remain depressed. They will bring us closer to our aspiration of extending our presence in healthcare and in the high-growth-high-margin segment. Global presence, a unique technology portfolio and close partnership with our customers will give us a competitive advantage in achieving these goals.

Thank you for your attention and support."

René Willi hands back to the Chairman, who thanks him and adds the following remarks:

"2024 was a year of change for our company. When we appointed René Willi as our new CEO, we communicated our commitment to shifting gears and transitioning to a new era of customer-centricity and profitable growth fueled by innovation and operational excellence. As you have just seen, we have made progress in 2024 towards achieving our ambitious goals and demonstrating our resilience in a rapidly changing global environment.

However, 2024 was not only a year of change, but also a year in which we have created a sound foundation for our future growth. With our refined strategy, we have outlined a clear path towards achieving our aspiration to be a market leader in demanding fluid management and high-precision delivery devices. Our strategic priorities focus on adapting our organizational setup to enhance our customer proximity, pace of innovation and to ensure clear accountability. I'm impressed by the speed and determination in which the management team is implementing our key initiatives:

We have re-established a culture where the customer is at the center of everything we do. To enable this transformation, we have taken actions to increase service levels, for which we have already received very positive feedback from our customers and our teams in the fourth quarter. We have initiated a comprehensive organizational adaptation, empowering our business units, simplifying reporting structures as well as our processes, and reducing complexity to increase speed and agility to improve customer experience.

Our strategy remains to increase our focus on high-growth-high-margin niches in the healthcare segment, leveraging our unique competence in complex fluid management and high precision delivery devices. Prerequisite to this strategy is a stringent focus and discipline when it comes to capital and resource allocation. For this purpose, we launched our growth and efficiency program aimed at unleashing growth by re-allocating resources to our strategic priorities and improving our performance by reducing costs. As René mentioned in the business review, we target significant cost out over the next two years, with most of the actions to be executed in 2025 and a significant portion of the savings expected to have an impact already in 2025. Our primary focus is on reducing headquarters and support functions, automating production processes, simplifying process flows and insourcing differentiating activities. We will continue to invest in our production capabilities, with a focus on Atlanta in 2025, as well as in R&D, which will ensure we continue to be at the forefront of innovation in both our segments.

Our proposed dividend, on which you'll vote in a few minutes, reflects the resilience of our company and our confidence in medmix' future performance."

The Chairman closes his remarks by expressing his great appreciation and thanking shareholders, employees, customers and partners.

The Chairman announces that, at today's Annual General Meeting, 28,941,727 registered shares are represented, out of which 1,248,658 are represented by shareholders and 27,693,069 are represented by the independent proxy. This means that 70,1% of the registered share capital is represented today. Each registered share has a nominal value of CHF 0.01.

## Agenda item 1: Annual report 2024

---

### Agenda item 1.1: Business review, financial statements of medmix Ltd and consolidated financial statements 2024

The annual report, containing the business review, the financial statements and the consolidated financial statements, as well as the reports of the auditor are available on medmix' website.

The Chairman reiterates the key numbers from the income statement of the holding company, medmix Ltd, for the financial year 2024: The parent company's accounts show an income of CHF 28.0 million and expenses of CHF 8.9 million, resulting in a net profit of CHF 19.0 million.

The Chairman mentions that medmix Ltd's statutory financial statements have been prepared according to the accounting principles of the Swiss Code of Obligations.

The auditor's reports are included in the section "Financial Reporting" of the annual report on pages 185 et seqq. (for the consolidated financial statements) and on pages 201 et seqq. (for the financial statements of medmix Ltd). The page numbers refer to the annual report that can be downloaded in PDF format from the website. The Chairman thanks KPMG AG for their work.

The Chairman states that the representative of KPMG AG, who is present, indicated, prior to the Annual General Meeting, that he has no additional comment to make on the reports.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the business review, the financial statements of medmix Ltd and the consolidated financial statements 2024 be approved.

The Chairman announces that the Annual General Meeting approved the business review, the financial statements of medmix Ltd and the consolidated financial statements 2024 with the following results:

Majority	14,470,864
Votes in favor	28,830,174
Votes against	42,013
Abstentions	69,540

The Chairman states that medmix demonstrated a solid performance in 2024 despite challenging conditions. This would not have been possible without the dedication of medmix' employees. On behalf of the Board of Directors and the Executive Committee, the Chairman thanks all the employees for their commitment and performance.

### Agenda item 1.2: Advisory vote on the compensation report 2024

The Chairman explains that agenda item 1.2 is a non-binding advisory vote.

The compensation report sets out the basic principles of medmix' compensation policy and plans, as well as the compensation of the members of the Board of Directors and the Executive Committee. The Chairman further explains the compensation policy of medmix for the Board of Directors and the Executive Committee.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the compensation report 2024, as included in the annual report 2024, be approved in a non-binding advisory vote.

The Chairman announces that the Annual General Meeting approved the compensation report 2024 in a non-binding advisory vote with the following results:

Majority	14,470,864
Votes in favor	21,210,649
Votes against	7,629,921
Abstentions	101,157

### **Agenda item 1.3: Sustainability report 2024**

The sustainability report sets out in detail the non-financial governance and strategy-specific elements that supplement the information presented in other sections of the annual report 2024, describing medmix' people and culture focus, and addressing the approach, measures and progress against priorities and commitments on environmental matters, in particular CO<sub>2</sub> goals, social issues, employee-related issues, respect for human rights and medmix' efforts in combating corruption. The Chairman further refers to medmix' non-financial achievements and highlights.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Board of Directors proposes that the sustainability report 2024, as included in the annual report 2024, be approved.

The Chairman announces that the Annual General Meeting approved the sustainability report 2024 with the following results:

Majority	14,470,864
Votes in favor	27,132,609
Votes against	1,674,608
Abstentions	134,510

### **Agenda item 2: Appropriation of annual result**

---

The Board of Directors proposes to allocate the total balance of CHF 35,057,604, comprising the net profit for 2024 of CHF 19,032,695 and the retained profits of CHF 16,024,909, as follows: CHF 20,395,376 as ordinary dividend and CHF 14,662,228 as balance to be carried forward.

The Chairman explains that medmix pursues a dividend policy that takes into account the company's liquidity as well as its economic situation.

The proposal of the Board of Directors, before deduction of 35% Swiss withholding tax, will amount to CHF 0.50 per share, payable on 29 April 2025. All shares held by medmix Ltd and its subsidiaries on the record date are not entitled to dividends.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has approved the appropriation of the annual result proposed by the Board of Directors with the following results:

Majority	14,470,864
Votes in favor	28,111,304
Votes against	786,183
Abstentions	44,240

### **Agenda item 3: Discharge**

---

The Board of Directors proposes that discharge be granted to the members of the Board of Directors and the Executive Committee for the financial year 2024.

The Chairman reminds the shareholders that, according to Art. 695 CO, the persons who were involved in the management of the company do not have the right to vote on the present agenda item. Furthermore, the Chairman states that Tiwel Holding AG voluntarily also accepted the same restriction for all shares held by it.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the vote.

The Chairman notes that the Annual General Meeting has granted discharge to the members of the Board of Directors and the Executive Committee with the following results:

Majority	6,081,507
Votes in favor	11,430,443
Votes against	581,180
Abstentions	151,389

The Chairman thanks the shareholders for the trust they have placed in the Board of Directors and the Executive Committee.

### **Agenda item 4: Compensation of the Board of Directors and the Executive Committee**

---

The Chairman comes to the vote on the compensation of the Board of Directors and the Executive Committee. He mentions that agenda item 4 is divided into two sub-items with two separate votes: part 1, "Compensation of the Board of Directors", and part 2, "Compensation of the Executive Committee".

For detailed explanations on the approval of the submitted compensation, the Chairman refers to the separate report of the Board of Directors that the shareholders received with the invitation to this Annual General Meeting.

On the compensation of the Board of Directors, the Chairman states that the maximum total amount submitted for approval relates to the compensation for the term from today's Annual General Meeting to the Annual General Meeting 2026.

The proposed maximum total amount is CHF 1,500,000 and remains unchanged from last year. The members of the Board of Directors only receive a fixed compensation to ensure their independence. They do not receive any variable or performance-related compensation nor are they entitled to participate in medmix' pension plans. The compensation of the Board of Directors is partly paid in cash and partly in restricted stock units.

On the compensation of the Executive Committee, the Chairman states that the proposed maximum total amount relates to the compensation for the financial year 2026. The proposed amount of CHF 8,500,000, unchanged compared to last year, covers the maximum total compensation of the members of the Executive Committee. The total compensation consists of a fixed base salary and a variable component. The variable component comprises a short-term performance-related bonus (in cash) and a long-term performance-related performance share unit plan. This system is designed to motivate above-average performance and to recognize this performance accordingly.

The Chairman mentions that this is a maximum amount. In accordance with legal requirements, the calculation of the maximum total amount of compensation for the Executive Committee takes into account the potential maximum amounts under the variable component of compensation, *i.e.*, both the short-term and long-term incentive systems.

The compensation actually paid out will be disclosed in the compensation report for the financial year 2026 which will be submitted to the shareholders for an advisory vote.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the votes.

#### **Agenda item 4.1: Compensation of the Board of Directors**

The Annual General Meeting votes on the approval of the total amount for the compensation of the Board of Directors for the term from the Annual General Meeting 2025 until the end of the Annual General Meeting 2026 in the maximum amount of CHF 1,500,000.

The Chairman notes that the Annual General Meeting approved the maximum total compensation of the Board of Directors for the term from the Annual General Meeting 2025 until the end of the Annual General Meeting 2026 with the following results:

Majority	14,470,864
Votes in favor	27,878,205
Votes against	927,938
Abstentions	135,584

#### **Agenda item 4.2: Compensation of the Executive Committee**

The Chairman continues with the vote on agenda item 4.2.

The Annual General Meeting votes on the approval of the total amount for the compensation of the Executive Committee for the financial year 2026 in the maximum amount of CHF 8,500,000.

The Chairman notes that the Annual General Meeting has approved the maximum total compensation of the Executive Committee for the financial year 2026 with the following results:

Majority	14,470,924
Votes in favor	27,075,037
Votes against	1,728,853
Abstentions	83,957

## Agenda item 5: Election of the Board of Directors

---

The Chairman mentions that agenda item 5 is divided into two sub-items with separate votes, namely agenda item 5.1 "Re-election of the Chairman of the Board of Directors" and agenda item 5.2 "Re-election of the other members of the Board of Directors".

### Agenda item 5.1: Re-election of the Chairman of the Board of Directors

Marco Musetti takes over and states that the Board of Directors proposes that the shareholders re-elect Rob ten Hoedt as member and Chairman of the Board of Directors for a term until the end of the Annual General Meeting 2026.

Marco Musetti explains that Rob ten Hoedt has been elected as a member of the Board of Directors and as a member of the Nomination and Remuneration Committee at the Annual General Meeting 2022, while he was elected as Chairman of the Board of Directors at the Annual General Meeting 2023. Rob ten Hoedt was Executive Vice President & President, Europe, Middle East & Africa (EMEA) and Asia-Pacific (APAC) and a member of the Executive Committee of Medtronic until he retired in August 2024. For a detailed biography of Rob ten Hoedt, Marco Musetti refers shareholders to medmix' website.

Marco Musetti opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, Marco Musetti proceeds to the election.

Marco Musetti announces that the Annual General Meeting has re-elected Rob ten Hoedt as member and Chairman of the Board of Directors with the following results:

Majority	14,470,924
Votes in favor	26,652,300
Votes against	2,201,087
Abstentions	88,460

Marco Musetti congratulates the Chairman on his re-election and hands back to him.

### Agenda item 5.2: Re-election of the other members of the Board of Directors

The Chairman states that all current members of the Board of Directors stand for re-election, and then introduces the members as follows:

**Marco Musetti** was elected as a member of the Board of Directors at the Annual General Meeting 2021. He has been vice-chairman of the Board of Directors since the Annual General Meeting 2021 and chairman of the Audit Committee since the Annual General Meeting 2022. He has been a member of the Board of Directors at several international companies, and was also a member of the Board of Directors of Sulzer Ltd from 2011 to April 2021.

**Barbara Angehrn** was elected as a member of the Board of Directors at the Annual General Meeting 2022. She has also been a member of the Nomination and Remuneration Committee since the Annual General Meeting 2022. Barbara Angehrn has been Chief Executive Officer of Asceneuron since October 2023.

**Susanne Hundsbaek-Pedersen** was elected as a member of the Board of Directors at the Annual General Meeting 2024. Since then, she has also been a member of the Audit Committee. Since January 2021, Susanne Hundsbaek-Pedersen has been Executive Vice President, Head of Global Technical Operations at F. Hoffmann-La Roche Ltd in Basel.

**Daniel Flammer** was elected as a member of the Board of Directors at the Annual General Meeting 2022. He has also been a member of the Audit Committee since then. Daniel Flammer has been Managing Partner of AR Financial Advisory AG in Zurich since April 2018.

**David Metzger** was elected as a member of the Board of Directors at the Annual General Meeting 2022. At the Annual General Meeting 2023, he was also elected as a member of the Nomination and Remuneration Committee. David Metzger is currently working for Liwet Holding AG.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Chairman starts with the re-election of Marco Musetti under agenda item 5.2.1. The Board of Directors proposes to re-elect Marco Musetti as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Marco Musetti to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	23,443,675
Votes against	5,348,655
Abstentions	149,517

The Chairman continues with the re-election of Barbara Angehrn under agenda item 5.2.2. The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	28,729,389
Votes against	111,903
Abstentions	100,555

The Chairman continues with the re-election of Susanne Hundsbaek-Pedersen under agenda item 5.2.3. The Board of Directors proposes to re-elect Susanne Hundsbaek-Pedersen as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Susanne Hundsbaek-Pedersen to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	28,799,054
Votes against	78,644
Abstentions	64,149

The Chairman continues with the re-election of Daniel Flammer under agenda item 5.2.4. The Board of Directors proposes to re-elect Daniel Flammer as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Daniel Flammer to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	22,472,236
Votes against	5,300,270
Abstentions	1,169,341

The Chairman continues with the re-election of David Metzger under agenda item 5.2.5. The Board of Directors proposes to re-elect David Metzger as a member of the Board of Directors for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger to the Board of Directors for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	26,690,940
Votes against	2,094,833
Abstentions	156,074

The Chairman mentions that the Board of Directors will reconstitute itself following the Annual General Meeting. This concerns the election of the vice-chairperson of the Board of Directors, the election of the chairperson of the Nomination & Remuneration Committee, as well as the election and constitution of the Audit Committee, *i.e.*, the election of its members and chairperson.

#### **Agenda item 6: Re-election of the Nomination & Remuneration Committee**

---

The Chairman states that the Board of Directors proposes that shareholders re-elect Barbara Angehrn, Rob ten Hoedt and David Metzger as members of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting. Barbara Angehrn and Rob ten Hoedt joined the Nomination & Remuneration Committee in 2022, while David Metzger was elected as a member at the Annual General Meeting 2023.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the re-elections.

The Board of Directors proposes to re-elect Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected Barbara Angehrn as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	27,668,982
Votes against	1,172,409
Abstentions	100,456

The Chairman hands over to Marco Musetti who continues with the re-election of Rob ten Hoedt under agenda item 6.2. The Board of Directors proposes to re-elect Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

Marco Musetti notes that the Annual General Meeting has re-elected Rob ten Hoedt as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	23,767,722
Votes against	5,071,327
Abstentions	102,798

Marco Musetti hands back over to the Chairman who continues with the re-election of David Metzger under agenda item 6.3. The Board of Directors proposes to re-elect David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting.

The Chairman notes that the Annual General Meeting has re-elected David Metzger as a member of the Nomination & Remuneration Committee for a term until the end of the next Annual General Meeting with the following results:

Majority	14,470,924
Votes in favor	24,732,127
Votes against	4,056,802
Abstentions	152,918

#### **Agenda item 7: Re-election of the Auditor**

---

The Chairman continues with the re-election of the auditor.

The Board of Directors proposes to re-elect KPMG AG, Zurich, as auditor for the financial year 2025.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected KPMG AG as auditor with the following results:

Majority	14,470,924
Votes in favor	28,788,670
Votes against	37,399
Abstentions	115,778

#### **Agenda item 8: Re-election of the Independent Proxy**

---

The Chairman continues with the re-election of the independent proxy under agenda item 8.

The Board of Directors proposes to re-elect Proxy Voting Services GmbH, Zurich, for a term until the end of the next Annual General Meeting as the independent proxy. Proxy Voting Services GmbH fulfils the requirements of independence, in particular because it is not connected to medmix through any other activities.

The Chairman opens the discussion on this agenda item. As there are no questions or comments from the floor on this agenda item, the Chairman proceeds to the election.

The Chairman notes that the Annual General Meeting has re-elected Proxy Voting Services GmbH, Zurich, for a term until the end of the next Annual General Meeting as independent proxy with the following results:

Majority	14,470,924
Votes in favor	28,800,940
Votes against	13,103
Abstentions	127,804

Martin Lutz (Bülach), shareholder, asks the Chairman to give a brief overview of medmix and inquires what the consequences of the newly implemented U.S. tariffs are. The Chairman gives shareholders a brief overview of medmix, explaining medmix' business units and touching upon medmix' strategy. With regard to the newly implemented tariffs, the Chairman states that medmix has manufacturing capabilities in the United States, in Europe and in Asia, allowing medmix to execute a local for local manufacturing. The Chairman points out that these different manufacturing sites may be an important instrument for medmix' competitive position.

As there are no further questions or comments, the Chairman closes this year's Annual General Meeting. He thanks shareholders for their interest and continued trust in medmix. He invites shareholders to a reception.

Closing of the meeting: 11:20 a.m.

The Chairman:

[SIGNATURE]

\_\_\_\_\_  
Rob ten Hoedt

The Secretary:

[SIGNATURE]<sup>1</sup>

\_\_\_\_\_  
Xavier Schops

<sup>1</sup> Original versions, signed by the Chairman and Secretary are maintained at the registered office.